Company Overview and News

to your dashboard

Headline News

Theravance Shares Rise on Approval of Glaxo's COPD Therapy

2017-11-17 zacks
Theravance Biopharma, Inc.’s (TBPH - Free Report) shares rose almost 6.5% on Thursday following the approval of GlaxoSmithKline plc’s (GSK - Free Report) chronic obstructive pulmonary disease ("COPD") therapy, Trelegy Ellipta in Europe. Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva, Inc. (INVA - Free Report) on global sales of Trelegy Ellipta. (36-0)

Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

2017-11-17 zacks
GlaxoSmithKline plc (GSK - Free Report) and partner Innoviva, Inc. (INVA - Free Report) announced that their triple combination therapy was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with chronic obstructive pulmonary disease (COPD). (36-0)

Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell

2017-11-17 investorplace
GlaxoSmithKline Plc (NYSE:GSK) is one of 132 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 782 company GICS Health Care sector. GSK's market value is $86.3 billion which places it in the top decile in its industry group. The ranking for GSK by Portfolio Grader places it 88 among the 132 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 511 among the 782 companies in the sector, and number 3,219 in the nearly 5,000 company Portfolio Grader universe. (3-0)

Theravance Biopharma: Undervalued With Catalysts

2017-11-16 seekingalpha
There is significant opportunity for norepinephrine serotonin reuptake inhibitor TD-9855 in patients with nOH considering the drug's differentiated profile and current sales of competitor Northera. (7-0)

Emergent BioSolutions: More Than An Emerging Biotech

2017-11-16 seekingalpha
Emergent is an underrated $1.6-billion market cap biotech company that operates in the niche infectious disease market. (1-0)

Amarin: A Likely Runner In 2018

2017-11-15 seekingalpha
Shares have risen by 20% since my initial article in May and I believe the uptrend will remain intact in 2018. (142-0)

AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

2017-11-15 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to its asthma disease candidate, benralizumab. Benralizumab, approved as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older, will be marketed by the trade name of Fasenra. (237-0)

Glaxo And Pfizer Are Top 'Safer' Dividend Healthcare Gainers For November

2017-11-15 seekingalpha
GSK, the top "safer" dividend healthcare stock, with a 32.1% net gain was 3x Pfizer's 10.4% second-place effort, and 10x JNJ's eighth-place gains as per analyst targets. (97-0)

9 More Companies Whose Dividend Is in Danger

2017-11-14 investorplace
All things considered, it can’t be terribly surprising General Electric Company (NYSE:GE) opted to reduce its dividend. Whispers of such a move have been circulating for a while, and it’s not exactly a big secret that GE can’t actually afford to pay out what it’s been passing along as dividends to shareholders of late. (198-0)

Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In

2017-11-14 seekingalpha
GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17. (174-0)

Glaxo's Subcutaneous Formulation of Benlysta Approved in EU

2017-11-14 zacks
GlaxoSmithKline plc (GSK - Free Report) announced approval in EU for a new self-injectable subcutaneous ("SC") formulation of Benlysta for systemic lupus erythematosus ("SLE"). The subcutaneous formulation is already approved in the United States. (101-0)

Deleterious Earnings Momentum Drop GlaxoSmithKline (GSK) to Sell

2017-11-10 investorplace
GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK puts it 77 among the 133 companies in this industry group, giving it a below-average spot. GSK is ranked in the third quartile of the sector with a ranking of 499 among the 785 companies in the sector and number 3,205 in the 5000 company Portfolio Grader company universe. (3-0)

2 High Quality U.K. Dividend Stocks For Your Portfolio.

2017-11-10 seekingalpha
Investors can sign up for Bargain Hunter to receive my real time trades in these and other stocks. (69-0)

Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

2017-11-10 zacks
Earnings remained in focus this week with companies like AstraZeneca (AZN - Free Report) reporting third quarter results. Meanwhile, companies like Roche (RHHBY - Free Report) and Merck & Co., Inc. (MRK - Free Report) were in the news due to regulatory updates. Recap of the Week’s Most Important Stories Mixed Results from AstraZeneca: AstraZeneca’s third quarter results were mixed with the company missing on earnings but beating on revenues. (56-0)

UPDATE 1-UK Stocks-Factors to watch on Nov 10

2017-11-10 reuters
Nov 10 (Reuters) - Britain’s FTSE 100 index is seen opening 13 points higher at 7,497 on Friday, according to financial bookmakers, with futures up 0.11 percent ahead of the cash market open. (55-1)

CUSIP: G3910J112